Lygenesis, a biotech startup based in Pittsburgh, has raised over $37M to create cell therapies for life-threatening diseases. Founded by CSO Eric Lagasse, (PharmD, PhD), CMO Paulo Fontes (MD, FACS) and CEO Michael Hufford (PhD), Lygenesis has developed treatments for Type 1 diabetes, end-stage renal disease, autoimmune diseases and aging. Through I-Corps customer discovery, they identified a critical bottleneck in organ transplant that they could solve with innovations in cell therapies. Currently, Jacqueline Jeha, MPH and Jennifer Taylor are leading the clinical trials of Lygenesis’ therapy of ESLD.
